CONSOLIDATED ENTITIES - Pulmoquine Therapeutics, Inc. (Details) - USD ($) $ in Thousands		12 Months Ended
	Apr. 20, 2020	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
CONSOLIDATED ENTITIES
Total assets		$ 999,570	$ 724,826
Cash balance		246,487	278,096
Total operating expenses		15,671	$ 14,656	$ 22,753
Pulmoquine Therapeutics, Inc.
CONSOLIDATED ENTITIES
Percentage of outstanding shares acquired	90.90%
Total assets		3,500
Cash balance		3,200
Other current assets		300
Net loss		2,200
Total operating expenses		$ 2,000
Pulmoquine Therapeutics, Inc. | Series A preferred stock
CONSOLIDATED ENTITIES
Securities to be purchased	5,808,550
Payments for acquire variable interest	$ 5,000